Introduction {#Sec1}
============

Cancer of the uterine cervix is one of the most common cancers among women worldwide and is particularly prevalent in developing nations.^[@CR1]^ Platinum-based combination chemotherapy has been the standard first-line chemotherapy for recurrent or advanced cervical cancer.^[@CR2]^ Currently, paclitaxel and cisplatin combined with bevacizumab is considered the preferred first-line regimen in metastatic or recurrent cervical cancer.^[@CR3]^ However, first-line chemotherapy options for stage IVB, recurrent, or persistent cervical cancers are limited; there are still unmet medical needs for new agents with favourable benefit-risk profiles that maintain quality of life.

In a previous study, Katsumata et al.^[@CR4]^ reported promising results for S-1, an oral fluoropyrimidine-based anticancer agent, as a single agent, with an overall response rate (ORR) of 30.6% and median time to progression of 5.2 months in patients with advanced or recurrent cervical cancer. Furthermore, S-1 plus cisplatin has shown efficacy with acceptable toxicity for the treatment of gastric and lung cancer.^[@CR5],[@CR6]^ Given that platinum-based combinations have been widely used for patients with advanced cervical cancer, adding S-1 to cisplatin was expected to be an effective treatment option.

We therefore compared the efficacy and safety of S-1 plus cisplatin with cisplatin alone as first-line chemotherapy in patients with stage IVB, recurrent, or persistent cervical cancer.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

This open-label, multicentre, parallel-group, randomised, phase III study, conducted at 69 institutions in Japan, Korea, and Taiwan, was designed to compare the efficacy and safety of S-1 plus cisplatin (study group) with cisplatin alone (control group) in patients with stage IVB, recurrent, or persistent cervical cancer (Supplementary Table [S1](#MOESM3){ref-type="media"}). At the time this study was planned, cisplatin alone was one of the effective treatments available for this patient population.^[@CR7]^ In the past, a number of cisplatin-based chemotherapies have been evaluated over cisplatin alone with respect to overall survival (OS). Although only topotecan plus cisplatin showed a survival advantage over cisplatin alone in the GOG179 trial,^[@CR8]^ the use of this regimen has not become widespread because of its greater toxicity as compared to other available regimens. So far, only one study suggests a survival benefit for topotecan. The GOG204 trial, which compared different cisplatin doublets (paclitaxel, vinorelbine, gemcitabine, or topotecan), was terminated early after an interim analysis showed no improvement in OS with any regimen, compared to paclitaxel plus cisplatin.^[@CR9]^ Because paclitaxel plus cisplatin was considered the most preferable treatment in terms of OS, progression-free survival (PFS), and ORR in the GOG204 trial, this combination became widely used. Paclitaxel plus carboplatin has also demonstrated noninferiority to paclitaxel plus cisplatin (JCOG0505 trial).^[@CR10]^ Based on these results, paclitaxel plus platinum-based drug became frequently used; however, paclitaxel plus cisplatin failed to show superiority in OS compared with cisplatin alone in the GOG169 trial.^[@CR11]^ Therefore, we considered cisplatin 50 mg/m^2^ to be the most reasonable candidate for the control arm of this study. Patients were randomly assigned (1:1) to the study group or the control group using an interactive web response system. Randomisation was stratified using a minimisation assignment based on the presence/absence of disease in a previously irradiated field, previous use of platinum-based therapy, and institution. After the investigators enrolled patients, the randomisation sequence was generated by The Kitasato Institute Clinical Trial Coordinating Center (Tokyo, Japan), independent of the study sponsor. The protocol summary is available in Supplementary Material [S1](#MOESM1){ref-type="media"}. The trial was registered at ClinicalTrials.gov (NCT00770874).

Patients {#Sec4}
--------

Briefly, patients had to be ≥20 years of age with histologically proven International Federation of Gynecology and Obstetrics (FIGO) stage IVB, recurrent, or persistent cervical carcinoma, with no chemotherapy or chemoradiotherapy after diagnosis of their disease. Patients were required to have adequate organ function and Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0--1. Main exclusion criteria were known hypersensitivity to 5-fluorouracil or cisplatin, previous treatment with S-1, or disease progression during platinum-based chemotherapy or chemoradiotherapy.

Treatment {#Sec5}
---------

Each treatment cycle lasted for 3 weeks, and cycles were repeated until the patient met one of the discontinuation criteria: either disease progression or unacceptable toxicity. In the study group, S-1 was administered orally twice daily from Day 1 to Day 14, followed by a 1-week rest. The initial dose of S-1 was determined according to the patient's body surface area at the time of registration: \<1.25 m^2^, 80 mg/day; ≥1.25 to \<1.5 m^2^, 100 mg/day; and ≥1.5 m^2^, 120 mg/day. Cisplatin 50 mg/m^2^ was administered intravenously on Day 1 with adequate hydration. Patients in the control group received the same regimen without S-1. Detailed criteria for suspension, resumption, initiation of subsequent cycle, and dose modification of the study treatment are defined in the study protocol (Supplementary Material [S2](#MOESM2){ref-type="media"}). Prophylactic use of granulocyte colony-stimulating factor was not permitted, and crossover treatment with S-1 was prohibited in the control group. If a patient developed drug-related adverse events (AEs) with either study drug, the treatment was discontinued but the patient was allowed to continue treatment with another drug.

Study endpoints {#Sec6}
---------------

The primary endpoint was OS, and the secondary endpoints were PFS, ORR, and safety. OS was defined as the period from the date of randomisation to death. PFS was defined as the period from the date of randomisation to disease progression or death. Survival information was obtained every 3 months after the end of treatment. Tumour imaging was performed at baseline and after every two cycles. Tumours were assessed by the investigator according to the Response Evaluation Criteria in Solid Tumors, version 1.0.^[@CR12]^ AEs and laboratory values were graded according to the Common Terminology Criteria for Adverse Events, version 3.0.

Statistical analyses {#Sec7}
--------------------

Sample size was calculated based on the survival endpoint reported in previous trials, with an expected median survival time (MST) in the control group of 9 months.^[@CR7]^ An improvement in MST of at least 39% from 9 months in the control group to 12.5 months in the study group, yielding a decreased hazard ratio (HR) of 0.72 (below the point estimate for topotecan plus cisplatin, GOG179 trial), was considered clinically relevant in this population. A total of 296 events (deaths) were required for a power of 80% at a two-sided alpha 5% to detect a difference in OS using an unstratified log-rank test. Based on a planned accrual of 24 months, a minimum follow-up of 18 months and an approximate rate of 5% loss to follow-up, a total of 360 patients (180 per group) were estimated to achieve the specified number of events in the scheduled follow-up.

The efficacy endpoints of OS and PFS were assessed in the full analysis set (FAS), which comprised all patients who received the study drugs in each assigned treatment group at randomisation, even if they received a treatment different from the assigned treatment. Safety was assessed in the as-treated population (ATP), which comprised all patients who initiated treatment in both treatment groups according to the actual treatment received by the patients. ORR was evaluated in the ORR-evaluable population, which included patients in the ATP with measurable disease (at least one target lesion) at baseline.

The superiority of the study group over the control group for the primary OS analysis was tested using an unstratified log-rank test. OS in each group was summarised using Kaplan--Meier curves, and was further characterised for MST and survival probability at 12 months, with the corresponding 95% confidence intervals (CIs). In addition, HRs were estimated using the Cox proportional hazards model with only treatment as a factor. PFS was analysed in the same way as OS. ORR was compared between the two groups using Fisher's exact test. Estimates for each group and differences were presented with associated 95% CIs.

The final statistical analysis was originally planned for 18 months after the last patient randomisation or when 296 events had occurred, whichever came later. Statistical analyses were performed with SAS software, version 9.2. All reported *P* values were two sided, and *P* values \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

A total of 375 patients were enrolled between September 2008 and April 2011 and randomised to the study group (189) or the control group (186); of these, 364 (188 in the study group; 176 in the control group) received study treatment (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1CONSORT diagram

The baseline characteristics of the patients were well balanced between the two groups (Table [1](#Tab1){ref-type="table"}). The majority of patients had recurrent disease (74.5% in the study group; 74.1% in the control group \[hereinafter in this order\]), a history of platinum-based therapy (64.4%; 63.8%), presence of disease in previously irradiated field (51.6%; 52.3%), and PS 0 (75.0%; 78.2%).Table 1Baseline patient characteristicsStudy group (*n* = 188)Control group (*n* = 174)Country of enrolment, *n* (%) Japan110 (58.5)105 (60.3) Korea52 (27.7)49 (28.2) Taiwan26 (13.8)20 (11.5)Age (years) Median5552.5 Range27**--**8428**--**81Body surface area (m^2^), *n* (%) \<1.252 (1.1)3 (1.7) 1.25 to \<1.581 (43.1)80 (46.0) ≥1.5105 (55.9)91 (52.3)ECOG performance status, *n* (%) 0141 (75.0)136 (78.2) 147 (25.0)38 (21.8)Disease status, *n* (%) IVB22 (11.7)27 (15.5) Recurrent140 (74.5)129 (74.1) Persistent26 (13.8)18 (10.3)Histological type, *n* (%) Squamous138 (73.4)132 (75.9) Adenosquamous8 (4.3)7 (4.0) Adeno37 (19.7)32 (18.4) Other5 (2.7)3 (1.7)Haemoglobin (g/dL), *n* (%) \<10.028 (14.9)27 (15.5) ≥10.0160 (85.1)147 (84.5)Prior radiotherapy, *n* (%)51 (27.1)44 (25.3)Prior chemoradiotherapy, *n* (%)113 (60.1)100 (57.5)Disease in previously irradiated field, *n* (%) Present97 (51.6)91 (52.3) Absent91 (48.4)83 (47.7)Previous history of platinum-based therapy, *n* (%) Yes121 (64.4)111 (63.8) No67 (35.6)63 (36.2)The full analysis set was used for the analysis. Study group, S-1 plus cisplatin; Control group, cisplatin*ECOG* Eastern Cooperative Oncology Group

Treatment {#Sec10}
---------

All patients discontinued the study treatment. The main reason for discontinuation was disease progression (Fig. [1](#Fig1){ref-type="fig"}).

In the ATP, the median number of cycles was 6 (range, 1--57) in the study group and 5 (range, 1--16) in the control group. The total dose of cisplatin was 255.0 mg/m^2^ in the study group and 250.0 mg/m^2^ in the control group.

Post-treatment therapy {#Sec11}
----------------------

In the study group, 69.1% of patients received post-treatment therapy, compared with 78.7% in the control group (Supplementary Table [S2](#MOESM3){ref-type="media"}). The most common first post-treatment therapy was chemotherapy (52.1% and 61.5% in the study and control groups, respectively), of which platinum-based therapy was administered to 34.0% and 44.8% of patients, respectively.

Efficacy {#Sec12}
--------

Although the timing for the statistical analysis had been previously established, the number of events was unlikely to reach 296 in the FAS, even after 4 years of follow-up. Therefore, we conducted the final statistical analysis at the cutoff date of 30 November 2015. A total of 294 death events (148, study group; 146, control group) occurred in the FAS by the cutoff date. MST (95% CI) was 21.9 months (18.6--25.8) in the study group and 19.5 months (17.0--24.3) in the control group. There was no statistically significant difference in the OS between the two groups (log-rank *P* = 0.125, HR 0.84, 95% CI 0.67--1.05) (Fig. [2a](#Fig2){ref-type="fig"}); the 1-, 3-, and 5-year survival rates (study group vs control group) were 79.7% vs 73.6%, 32.0% vs 22.9%, and 17.5% vs 15.7%, respectively. A prespecified forest plot of HR for OS showed the favourable impact of PS 0 (HR 0.74, 95% CI 0.57--0.96, *P* = 0.023) and of haemoglobin ≥10.0 g/dL (HR 0.77, 95% CI 0.60--0.99, *P* = 0.037) on OS in the study group compared with the control group (Fig. [2b](#Fig2){ref-type="fig"}).Fig. 2**a** Kaplan--Meier plot and **b** forest plot of hazard ratio for overall survival. Study group, S-1 plus cisplatin; Control group, cisplatin. CI confidence interval, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, OS overall survival

Median PFS was longer in the study group (7.3 months, 95% CI 6.7--8.1) compared with the control group, with a statistically significant difference (4.9 months, 95% CI 4.4--5.7) (log-rank *P* \< 0.001, HR 0.62, 95% CI 0.48--0.80) (Fig. [3a](#Fig3){ref-type="fig"}). The forest plot of HR for PFS is shown in Fig. [3b](#Fig3){ref-type="fig"}.Fig. 3**a** Kaplan--Meier plot and **b** forest plot of hazard ratio for progression-free survival. Study group, S-1 plus cisplatin; Control group, cisplatin. CI confidence interval; ECOG Eastern Cooperative Oncology Group, HR hazard ratio, PFS progression-free survival

ORR and disease control rate are shown in Table [2](#Tab2){ref-type="table"}. ORR was significantly higher (*P* \< 0.001) in the study group (43.8%, 95% CI 36.2--51.6) than in the control group (20.1%, 95% CI 14.0--27.5).Table 2Overall responses in patients receiving S-1 plus cisplatin or cisplatin aloneStudy group (*n* = 169)Control group (*n* = 149)*P* value^a^Best overall response, *n* (%)NA Complete response21 (12.4)6 (4.0) Partial response53 (31.4)24 (16.1) Stable disease54 (32.0)54 (36.2) Progressive disease24 (14.2)43 (28.9) Unknown^b^17 (10.1)22 (14.8)Overall response rate, *n* (%)74 (43.8)30 (20.1)\<0.00195% CI36.2--51.6%14.0--27.5%Disease control rate (CR + PR + SD), *n* (%)128 (75.7)84 (56.4)\<0.00195% CI68.6--82.0%48.0--64.5%The overall response rate-evaluable population was used. Study group, S-1 plus cisplatin; Control group, cisplatin.*CI* confidence interval, *CR* complete response, *NA* not applicable, *PR* partial response, *SD* stable disease.^a^*P* value was calculated using Fisher's exact test.^b^Unknown contains 'not assessable' or 'insufficient data'

Safety {#Sec13}
------

AEs were observed in 188/188 (100%) patients in the study group and 172/175 (98.3%) patients in the control group. The AE rate in the study group was higher than in the control group. The most frequent grade 3 or higher AEs (occurring in ≥10% of patients in either group) for the study group vs the control group were neutropaenia (52.7% vs 6.3%), anaemia (34.6% vs 17.1%), leucopaenia (32.4% vs 4.0%), anorexia (12.8% vs 2.9%), diarrhoea (11.2% vs 4.0%), hypokalaemia (11.2% vs 1.1%), and fatigue (10.6% vs 1.7%) (Table [3](#Tab3){ref-type="table"}). The incidence of febrile neutropaenia was 2.7 and 0% of patients in the study and control groups; 1.6 and 2.8% of patients in the study and control groups had genitourinary or anal fistulas; and 8.0 and 1.1% of patients in the study and control groups had alopecia, respectively. Discontinuation of the study treatment due to AEs occurred in 13.3% and 7.4% of patients in the study and control groups, respectively. The most common toxic effect leading to study discontinuation was gastrointestinal toxicity in the study group and hypersensitivity in the control group.Table 3All-grade adverse events ≥20% patients and grade 3 and higher adverse events ≥10% patients in either groupAdverse event, *n* (%)Study group (*n* = 188)Control group (*n* = 174)All gradeGrade ≥ 3All gradeGrade ≥ 3Haematological Neutropaenia148 (78.7)99 (52.7)65 (37.1)11 (6.3) Anaemia147 (78.2)65 (34.6)87 (49.7)30 (17.1) Leucopaenia92 (48.9)61 (32.4)52 (29.7)7 (4.0) Thrombocytopaenia90 (47.9)17 (9.0)26 (14.9)5 (2.9)Non-haematological Albumin decreased46 (24.5)6 (3.2)23 (13.1)2 (1.1) Hypokalaemia39 (20.7)21 (11.2)9 (5.1)2 (1.1) ALT (GPT) increased38 (20.2)3 (1.6)23 (13.1)2 (1.1) Creatinine increased38 (20.2)4 (2.1)39 (22.3)2 (1.1) Weight decreased38 (20.2)5 (2.7)10 (5.7)1 (0.6)Clinical symptoms Nausea153 (81.4)6 (3.2)134 (76.6)7 (4.0) Anorexia141 (75.0)24 (12.8)105 (60.0)5 (2.9) Fatigue109 (58.0)20 (10.6)79 (45.1)3 (1.7) Vomiting103 (54.8)12 (6.4)71 (40.6)4 (2.3) Diarrhoea94 (50.0)21 (11.2)51 (29.1)7 (4.0) Constipation61 (32.4)3 (1.6)48 (27.4)1 (0.6) Stomatitis59 (31.4)7 (3.7)16 (9.1)0 Skin hyperpigmentation48 (25.5)02 (1.1)0 Oedema peripheral41 (21.8)2 (1.1)16 (9.1)1 (0.6) Peripheral sensory neuropathy39 (20.7)3 (1.6)22 (12.6)0 Pyrexia38 (20.2)020 (11.4)1 (0.6)The as-treated population was used for the analysis. Study group, S-1 plus cisplatin; Control group, cisplatin.*ALT* alanine aminotransferase, *GPT* glutamic-pyruvic transaminase

Overall, 72 of 188 patients (38.3%) in the study group and 34 of 175 (19.4%) patients in the control group had serious AEs (SAEs). Fatal SAEs occurred in seven patients in the study group, of which myocardial ischaemia in one patient and disseminated intravascular coagulation and intra-abdominal haemorrhage in another patient were related to the study drugs. Three fatal SAEs were reported in the control group, but none of them were related to the study drug. No unexpected AEs were identified in either group.

Discussion {#Sec14}
==========

In this study in patients with stage IVB, recurrent, or persistent cervical cancer, S-1 plus cisplatin did not improve OS over cisplatin alone. However, adding S-1 to cisplatin significantly prolonged OS in patients with better physical condition (PS 0 or haemoglobin ≥ 10.0 g/dL). Moreover, S-1 in combination with cisplatin significantly improved PFS and ORR over cisplatin alone.

There are several reasons for the lack of a significant OS benefit despite improvements in PFS and ORR. First, although the PS criteria were different (ECOG PS in our study and JCOG0505 study vs Gynecologic Oncology Group \[GOG\] PS in the GOG204 and GOG240), the proportion of patients with PS 0 in the cisplatin-alone group in our study was higher than that in the GOG169 and GOG179 studies with the same treatment.^[@CR8],[@CR11]^ On the other hand, the proportion of patients with PS 0 in the S-1 plus cisplatin group was higher than that in the GOG204 and GOG240 studies, but similar to the JCOG0505 study.^[@CR9],[@CR10],[@CR13]^ Since PS is one of the prognostic factors for cervical cancer,^[@CR14]^ this might be one of the reasons for the prolonged OS observed in our study. Second, post-treatment therapy including subsequent salvage chemotherapy was used in this study. Over half of the patients in both groups received post-treatment therapy. The effect of greater use of post-treatment therapy on prolonged OS was also speculated in the JCOG0505 trial;^[@CR10]^ in fact, chemotherapy was used most frequently as post-treatment therapy. As a result, median survival may have been prolonged. Third, survival post-progression (SPP) in the S-1 plus cisplatin group was 14.6 months in this study. Broglio et al.^[@CR15]^ have reported that even if PFS is prolonged, OS may not show a benefit, especially for diseases with long median SPP. We thus re-calculated the statistical power of this study based on the observed OS and found the power to be 18.4%.

Notably, S-1 plus cisplatin significantly prolonged PFS to 7.3 months. Furthermore, other phase III studies have reported median PFS of 3.98 to 6.9 months with cisplatin-based doublet combinations and 8.2 months with paclitaxel and cisplatin combined with bevacizumab.^[@CR9],[@CR10],[@CR13]^ Although the patients' quality of life data are lacking in this study, S-1 plus cisplatin demonstrated a similar response in terms of PFS to these combination therapies. ORR was also significantly improved with S-1 in combination with cisplatin. Response rates of 27--48% have been obtained with cisplatin-based doublet combinations or paclitaxel and cisplatin combined with bevacizumab.^[@CR8],[@CR11],[@CR13]^ Remarkably, a complete response rate of 12.4% has been obtained with S-1 plus cisplatin and was comparable to cisplatin plus paclitaxel plus bevacizumab.

Advanced cervical cancer is known to predispose patients to fistulas. Fistulas occurred in 1.6 and 6% of patients with S-1 plus cisplatin and bevacizumab combination therapy, respectively. Overall, the toxicity increased with S-1 plus cisplatin compared with cisplatin alone, but the incidence of toxicity was similar to or lower than that with cisplatin-containing doublet and triplet including bevacizumab combination therapies.^[@CR9],[@CR13]^ Myelosuppression were the major AEs in patients receiving S-1 plus cisplatin; however, the incidence of grade 3 or worse adverse events of anaemia, neutropaenia, thrombocytopaenia in the S-1 plus cisplatin group, except for topotecan plus cisplatin regimen in GOG204, was similar in the GOG204 and JCOG0505 studies. The incidence of grade 3 or worse leucopoaenia and febrile neutropaenia in the cisplatin group was lower than that in the GOG204 and JCOG0505 studies.^[@CR9],[@CR10]^ The S-1 plus cisplatin regimen demonstrated a tolerable safety profile in patients with stage IVB, recurrent, or persistent cervical cancer.

Patients with stage IVB, recurrent, or persistent cervical cancer are rarely curable. Therefore, selection of combination chemotherapy considering the toxicity profile and patient preference is important. For example, alopecia may worsen a patient's quality of life and lead to interference with treatment. Alopecia occurred in 64.3% of patients treated with paclitaxel plus cisplatin.^[@CR11]^ In contrast, 8% of patients experienced grade 1, but not grade 2, alopecia with S-1 plus cisplatin in this study.

We chose cisplatin 50 mg/m^2^ as the control arm of this study and considered the validity of the study results by comparing the efficacy and safety of cisplatin monotherapy in this study with those of other phase III studies. The OS of 19.5 months in the cisplatin-alone group was much longer than that reported in other studies (6.5--9.3 months) with the same therapy.^[@CR8],[@CR11]^ On the other hand, PFS in the control group was similar to the PFS reported in other studies (2.8--4.5 months).^[@CR8],[@CR11],[@CR16]--[@CR18]^ Further, the SPP in this study was 14.6 months. According to the study by Broglio et al.^[@CR15]^, if the SPP exceeds 12 months, OS may be affected, which may explain the lack of an OS advantage in the current study. As for myelosuppression, the safety results were similar to the other phase III studies.

These results suggest that S-1 plus cisplatin offers a better response than S-1 or cisplatin monotherapy and may be one of the first-line chemotherapy options in patients with FIGO stage IVB, recurrent, or persistent cervical cancer, especially for those in better physical condition (PS 0 or haemoglobin ≥ 10.0 g/dL), as seen in the forest plot analysis of OS. However, a limitation of this study is that the optimal clinical positioning of S-1 plus cisplatin among other combination chemotherapies for this population is unclear, because this study did not include combination chemotherapy as a comparator.

To further improve effectiveness, we are considering S-1 plus cisplatin with bevacizumab because overlapping toxicity is minimal. Although treatment schedule and dose are different, S-1 plus bevacizumab demonstrated acceptable toxicity in patients with metastatic colorectal cancer.^[@CR19],[@CR20]^ S-1 might be a good candidate for combination therapy with bevacizumab for advanced cervical cancer.

In conclusion, S-1 plus cisplatin did not show superiority over cisplatin alone in OS. S-1 plus cisplatin may provide some benefit as first-line chemotherapy for patients with FIGO stage IVB, recurrent, or persistent cervical cancer in terms of PFS and ORR compared with cisplatin alone, although contribution to survival is unclear. Given that the standard therapy for this population has changed in the course of this study, further studies to compare with combination therapy as a comparator are warranted to confirm the clinical positioning of S-1 combined with cisplatin for this population.
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